In a germline BRCA2 positive pt with NSCLC after chemoIO frontline and taxotere as a second line, would you consider PARP inhibitors?

This is a challenging situation and one I have encountered in clinic. The data for PARP inhibitors in NSCLC is limited. There have been limited trials for this specific population including NSCLC so I have extrapolated from the breast/ovarian experience.

For instance, there was a phase II clinical ...